Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?

Simply Wall StDec 9, 2024 02:56 ET

The listing application for sunshine guojian pharmaceutical's recombinant anti-IL-17A humanized monoclonal antibody injection 608 has been accepted by the National Medical Products Administration.

Shanghai, November 19, 2024 /PR Newswire/ -- Sunshine Guojian Pharmaceutical (stock code: 688336.SH) announced that the application for listing of its recombinant anti-IL-17A humanized monoclonal antibody injection (608), recently submitted to the National Medical Products Administration, was accepted on November 18, for the treatment of adult moderate to severe plaque psoriasis. 608 is an innovative monoclonal antibody against IL-17A independently developed by Sunshine Guojian Pharmaceutical. In August of this year, the key registration Phase III clinical trial of 608 for the treatment of adult moderate to severe plaque psoriasis completed unblinding and final statistical analysis, with all primary therapeutic effects.

PR NewswireNov 19, 2024 00:50 ET

Sunshine Guojian Pharmaceutical's Q3 Profit Jumps 50%; Shares Fall 3%

MT NewswiresOct 23, 2024 03:07 ET

Sansei Guojian: Third Quarter Report 2024

SZSIOct 22, 2024 12:00 ET · Announcements

Sunshine Guojian Pharmaceutical (688336.SH) released its performance for the first three quarters, with a net income of 0.233 billion yuan, a year-on-year increase of 42.18%.

Sunshine Guojian Pharmaceutical (688336.SH) released the third quarter report for 2024, with revenue of 9....

Zhitong FinanceOct 22, 2024 05:52 ET

Sunshine Guojian Pharmaceutical (688336.SH): The net income in the first three quarters was 0.233 billion yuan, an increase of 42.18% year-on-year.

On October 22, Sunshine Guojian Pharmaceutical (688336.SH) announced that the company's revenue for the first three quarters was 0.939 billion yuan, a year-on-year increase of 28.58%; the net income attributable to the shareholders of the listed company was 0.233 billion yuan, a year-on-year increase of 42.18%; the net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.217 billion yuan, a year-on-year increase of 44.46%; basic earnings per share was 0.38 yuan.

Gelonghui FinanceOct 22, 2024 05:34 ET